IDEAS home Printed from https://ideas.repec.org/a/adp/japbij/v1y2016i1p1-4.html
   My bibliography  Save this article

Current Standards of Systemic Therapies in Advanced Hepatocellular Cancer: A Review

Author

Listed:
  • Hossam Hosny

    (Orthopaedic Surgery Department, Sohag University, Egypt)

Abstract

Sorafenib a multikinase inhibitor is the only approved systemic therapy in the treatment of advanced hepatocellular cancer. No other targeted therapy have proved to be better, a lot of phase 3 trials with many targeted have shown no significant or clinically relevant activity. After SHARP trial no other trial with any other targeted therapy has shown any significant improvement in the treatment of hepatocellular cancer. EACH trial, a phase 3 randomized trial conducted on Asian patients proved better RR and PFS of FOLFOX4 regimen when compared to doxorubicin, showed efficacy and safety of FOLFOX4 protocol. In the light of so many negative phase 3 trials with targeted therapies, it seems only sorafenib still can be considered a standard therapy in advanced HCC.

Suggested Citation

  • Hossam Hosny, 2016. "Current Standards of Systemic Therapies in Advanced Hepatocellular Cancer: A Review," Anatomy Physiology & Biochemistry International Journal, Juniper Publishers Inc., vol. 1(1), pages 1-4, February.
    • Handle: RePEc:adp:japbij:v:1:y:2016:i:1:p:1-4
    DOI: 10.19080/APBIJ.2016.01.555551
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/apbij/pdf/APBIJ.MS.ID.555551.pdf
    Download Restriction: no
    File URL: https://juniperpublishers.com/apbij/APBIJ.MS.ID.555551.php
    Download Restriction: no
    File URL: https://libkey.io/10.19080/APBIJ.2016.01.555551?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    Anatomy Physiology; Biochemistry International Journal; Biochemistry; journal of biochemistry; biochemistry open access journals; open access biochemistry articles; biochemistry journals impact factor list; research journals ; research articles ; juniper publishers reivew;
    All these keywords.

    JEL classification:

    • R00 - Urban, Rural, Regional, Real Estate, and Transportation Economics - - General - - - General
    • Z0 - Other Special Topics - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:japbij:v:1:y:2016:i:1:p:1-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.